Literature DB >> 11914199

Anti-angiogenic therapy for uveal melanoma--more haste, less speed.

A W Stitt, T A Gardiner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11914199      PMCID： PMC1771083          DOI： 10.1136/bjo.86.4.368

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  6 in total

Review 1.  Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Authors:  R K Jain
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

Review 2.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

3.  The growth of the blood supply to melanoma transplants in the hamster cheek pouch.

Authors:  B A Warren; P Shubik
Journal:  Lab Invest       Date:  1966-02       Impact factor: 5.662

Review 4.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects.

Authors:  M Höckel; P Vaupel
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

5.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.

Authors:  L E Benjamin; D Golijanin; A Itin; D Pode; E Keshet
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

6.  Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity.

Authors:  T Alon; I Hemo; A Itin; J Pe'er; J Stone; E Keshet
Journal:  Nat Med       Date:  1995-10       Impact factor: 53.440
  6 in total
  4 in total

1.  Suppression of thrombospondin-1 expression during uveal melanoma progression and its potential therapeutic utility.

Authors:  Shoujian Wang; Aneesh Neekhra; Daniel M Albert; Christine M Sorenson; Nader Sheibani
Journal:  Arch Ophthalmol       Date:  2012-03

2.  Blood vessel maturation in human uveal melanoma: spatial distribution of neovessels and mature vasculature.

Authors:  Yolanda Piña; Colleen M Cebulla; Timothy G Murray; Armando Alegret; Sander R Dubovy; Hinda Boutrid; William Feuer; Lejla Mutapcic; Maria-Elena Jockovich
Journal:  Ophthalmic Res       Date:  2009-03-26       Impact factor: 2.892

3.  Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LH(BETA)T(AG) retinal tumors.

Authors:  Y Piña; C Decatur; Tg Murray; Sk Houston; D Gologorsky; M Cavalcante; L Cavalcante; E Hernandez; M Celdran; W Feuer; T Lampidis
Journal:  Clin Ophthalmol       Date:  2011-03-07

4.  Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LH(BETA)T(AG) retinal tumors.

Authors:  Yolanda Piña; Samuel K Houston; Timothy G Murray; Tulay Koru-Sengul; Christina Decatur; William K Scott; Lubov Nathanson; Jennifer Clarke; Theodore J Lampidis
Journal:  Clin Ophthalmol       Date:  2012-05-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.